Tag Archives: Alzheon

August, 2018

6 August
Alzheon Scientists Discover Endogenous Substance in Human Brain that Inhibits Formation of Key Driver of Alzheimer’s Disease

FRAMINGHAM, Mass.–(BUSINESS WIRE)–Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced the discovery of an endogenous substance in human brain that inhibits the formation of neurotoxic beta amyloid (Aβ) oligomers, which are key drivers of AD …
Share

25 July
Alzheon Presents New Findings in APOE4/4 Homozygous Patients with Mild Alzheimer’s Disease and Planned Confirmatory Clinical Trial with ALZ-801

FRAMINGHAM, Mass.–(BUSINESS WIRE)–Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease (AD) and other neurological and psychiatric disorders, today announced the upcoming presentation of data at the Alzheimer’s Association International Conference (AAIC) in Chicago on Wednesday, July 25th, 2018. The presentation at the …
Share

26 October
FDA Grants Fast Track Designation to Alzheon’s Investigational Alzheimer’s Disease Drug

FRAMINGHAM, Mass.–(BUSINESS WIRE)–Alzheon, Inc., a clinical stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease (AD) and other neurological and psychiatric disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead clinical investigational drug, ALZ-801, for the …
Share

11 March
Alzheon Announces Efficacy Analyses of Prior Studies Showing Clinically Meaningful Benefits of its Tramiprosate in Alzheimer’s Patients

FRAMINGHAM, Mass.–(BUSINESS WIRE)–Alzheon, Inc., today announced the presentations of new data analyses from two Phase 3 studies of tramiprosate in Alzheimer’s disease (AD) patients based on their APOE4 genotype. Tramiprosate is the biologically active agent of ALZ-801, a prodrug developed by Alzheon and currently being advanced into pivotal Phase 3 …
Share